Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus Hospitalizations among Infants Born at 33 to 35 Weeks Gestational Age in the Province of Quebec, Canada (RSV-QC Study)

2019 ◽  
Author(s):  
J. Papenburg ◽  
I. Defoy ◽  
E. Masse ◽  
G. Caouette ◽  
M. H. Lebel
2021 ◽  
Vol 5 (1) ◽  
pp. e000985
Author(s):  
Valeria Belleudi ◽  
Federico Marchetti ◽  
Marco Finocchietti ◽  
Marina Davoli ◽  
Antonio Addis

In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during five seasons (2014–2019), were considered according to different GA. Although RSV hospitalisations rate showed no significant changes, during different seasons in all GA, lower prevalence of palivizumab use in 2016 (0.8% vs 0.3%), returned to a higher level following the revoke of restrictions. Changes in reimbursement criteria were not associated with neonatal RSV hospitalisations rate but with a significant impact on palivizumab use.


2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Robin M. Pokrzywinski ◽  
Laura L. Swett ◽  
Jumi Yi ◽  
Veena R. Kumar ◽  
Kimmie K. McLaurin ◽  
...  

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S567-S568
Author(s):  
Evan J Anderson ◽  
Eric A Simões ◽  
Michael L Forbes ◽  
Paul A Checchia ◽  
Joseph B Domachowske ◽  
...  

2019 ◽  
Author(s):  
Kosuke Oikawa ◽  
Manabu Suzuki ◽  
Tomomasa Terada ◽  
Masaya Koganesawa ◽  
Motoichiro Sakurai ◽  
...  

Abstract Overview Background: In recent years, the epidemic of respiratory syncytial virus (RSV) has been seen in the summer. In daily clinical practice, we noted that RSV infection tends to become more severe and its treatment tends to be longer, particularly in patients hospitalized in the summer. Thus, we investigated factors associated with the progression to severe condition and the prolongation of treatment in RSV infection. Methods: Subjects were pediatric patients diagnosed with RSV infection and hospitalized for treatment during the 5 year s from April 2014 to March 2019. Information on age, sex, season of hospitalization, gestational age, and bronchial asthma of each subject was collected from inpatient medical records. Duration of oxygen administration was used as an index for treatment duration and the use of devices for severe cases as an index for severity. Multiple linear regression analysis and logistic regression analysis were performed to examine the variables associated with duration of oxygen administration and use of a device for severe cases. Results: Data from 298 patients were analyzed. Duration of oxygen administration was significantly associated with bronchial asthma (partial regression coefficient: 0.804, p = 0.010). Hospitalization in summer was significantly associated with use of a device for severe condition (adjusted odds ratio: 5.89, 95% confidence interval: 1.72-20.18). Conclusion: The present study showed that bronchial asthma is a risk factor for prolongation of treatment and infection in summer is a risk factor for progression to severe condition in cases of RSV infection. These findings suggested that children with bronchial asthma and infection in summer need to be treated carefully regardless of their age, sex, and gestational age.


2018 ◽  
Vol 35 (06) ◽  
pp. 541-544 ◽  
Author(s):  
Bosco Paes

AbstractHealthy, premature infants ≤35 weeks' gestational age (wGA) are universally recognized to be at an increased risk of perinatal morbidity and mortality. Serious respiratory syncytial virus (RSV) lower respiratory tract infection imposes an additional burden of illness on these infants following hospitalization. Incurred morbidities relative to term infants include longer lengths of hospital stay, admission to intensive care, and need for oxygen and mechanical ventilation, all of which are associated with increased hospital costs. The highest morbidities are experienced by premature infants who are youngest (<3 months' chronological age) and are of lower gestational age. Short- and long-term follow-up indicates that healthy preterm infants both of lower gestational age and who are late preterm have obstructive lung function at baseline, which is further compromised by RSV-related infection during infancy. There is increasing evidence that childhood exposure to an episode of RSV infection may set the stage for an abnormal respiratory function trajectory, which, in adulthood, leads to chronic obstructive pulmonary disease. Healthy premature infants <32 wGA merit RSV prophylaxis based on existing data, whereas moderate- and high-risk preterm infants 32 to 35 wGA should be selectively and cost-effectively targeted for prophylaxis using validated risk scoring tools and country-specific thresholds for funding.


2006 ◽  
Vol 25 (12) ◽  
pp. 1188-1190 ◽  
Author(s):  
Gunther Doering ◽  
Walter Gusenleitner ◽  
Bernd H. Belohradsky ◽  
Stefan Burdach ◽  
Bernhard Resch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document